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ABSTRACT Epstein-Barr virus (EBV) is typically acquired asymptomatically in child-
hood. In contrast, infection later in life often leads to infectious mononucleosis (IM),
a febrile illness characterized by anti-EBV IgM antibody positivity, high loads of circu-
lating latently infected B cells, and a marked lymphocytosis caused by hyperex-
pansion of EBV-speciﬁc CD8 T cells plus a milder expansion of CD56dim NKG2A
KIR natural killer (NK) cells. How the two situations compare is unclear due to the
paucity of studies on clinically silent infection. Here we describe ﬁve prospectively
studied patients with asymptomatic infections identiﬁed in a seroepidemiologic survey
of university entrants. In each case, the key blood sample had high cell-associated viral
loads without a marked CD8 lymphocytosis or NK cell disturbance like those seen in
patients during the acute phase of IM. Two of the cases with the highest viral loads
showed a coincident expansion of activated EBV-speciﬁc CD8 T cells, but overall
CD8 T cell numbers were either unaffected or only mildly increased. Two cases
with slightly lower loads, in whom serology suggests the infection may have been
caught earlier in the course of infection, also showed no T or NK cell expansion at
the time. Interestingly, in another case with a higher viral load, in which T and NK
cell responses were undetectable in the primary blood sample in which infection
was detected, EBV-speciﬁc T cell responses did not appear until several months later,
by which time the viral loads in the blood had already fallen. Thus, some patients
with asymptomatic primary infections have very high circulating viral loads similar to
those in patients during the acute phase of IM and a cell-mediated immune re-
sponse that is qualitatively similar to that in IM patients but of a lower magnitude.
However, other patients may have quite different immune responses that ultimately
could reveal novel mechanisms of host control.
IMPORTANCE Epstein-Barr virus (EBV) is transmitted orally, replicates in the throat,
and then invades the B lymphocyte pool through a growth-transforming latent in-
fection. While primary infection in childhood is usually asymptomatic, delayed infec-
tion is associated with infectious mononucleosis (IM), a febrile illness in which pa-
tients have high circulating viral loads and an exaggerated virus-induced immune
response involving both CD8 T cells and natural killer (NK) cells. Here we show
that in ﬁve cases of asymptomatic infection, viral loads in the blood were as high as
those in patients during the acute phase of IM, whereas the cell-mediated re-
sponses, even when they resembled those in patients during the acute phase of IM
in timing and quality, were never as exaggerated. We infer that IM symptoms arise
as a consequence not of the virus infection per se but of the hyperactivated immune
response. Interestingly, there were idiosyncratic differences among asymptomatic
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cases in the relationship between the viral load and the response kinetics, emphasiz-
ing how much there is still to learn about primary EBV infection.
KEYWORDS CD8 T cell, Epstein-Barr virus, host immune response, infectious
mononucleosis, NK cell, primary infection
Epstein-Barr virus (EBV), a gammaherpesvirus-1 with B cell growth-transformingability, is widespread in all human populations and is carried by most individuals as
a seemingly harmless infection (1). The virus is orally spread and is typically acquired
from close family contacts during infancy or early childhood, at which time infection is
almost always clinically silent. However, with rising standards of hygiene in the devel-
oped world, primary infection is increasingly being delayed until the second or third
decade of life. This often leads to infectious mononucleosis (IM), an illness whose
symptoms (fever, sore throat, cervical lymphadenopathy, and fatigue) range from mild
to severe and may take between 1 and 6 weeks to resolve (2). The proportion of
delayed primary infections that are symptomatic varies from 25 to 80% in different
reports, likely reﬂecting differences in the rigor of follow-up and clinical monitoring
(3–6). Such symptomatic cases have been extensively studied; indeed, what little is
known about the virology and immunology of primary EBV infection comes almost
exclusively from IM patients. Thus, by the time that IM symptoms appear (typically, 5 to
7 weeks after oral transmission), high levels of infectious virus can be detected in throat
washings, reﬂecting lytic virus replication in epithelial cells and probably also B cells at
oropharyngeal surfaces (7, 8). Also, by this time, the virus has already spread into the
general B cell pool as a latent infection. Many latently infected B cells can be found both
in tonsillar lymphoid tissue, where proliferating EBV growth-transformed cells exist
alongside cells with various degrees of more restricted latency (9, 10), and in the blood,
where most, if not all, cells have fully suppressed EBV growth-transforming protein
expression, moved to a resting state, and entered the recirculating memory B cell pool
(11). While virus shedding in the throat may continue at a high level for several months
after IM symptoms have waned (5, 12), the number of latently infected cells in the
blood tends to fall quickly during the disease course itself and then falls more gradually
to reach a stable set point over the following weeks and months (11, 13).
These events are coincident with a range of immune responses (14). Thus, IM can be
diagnosed serologically through the presence of IgM and rising titers of IgG antibodies
to the lytic EBV viral capsid antigen (VCA) in the absence of an IgG response to the
latent nuclear antigen EBNA1; thereafter, the IgM response gradually subsides, the
anti-VCA IgG titer stabilizes, and, months later, the anti-EBNA1 IgG response appears (2).
Blood collected from patients during the acute phase of IM is also characterized by a
large expansion of CD8 T cells with an activated effector (CD38 HLA-DR CCR7
CD45RA), apoptosis-prone (Bcl2low) phenotype. Many of these activated cells are
speciﬁc for immunodominant EBV antigens of the immediate early and early lytic cycle,
and these are accompanied by smaller (sometimes delayed) responses against latent
antigens (15, 16). The CD8 cell expansion in the blood is most marked in patients with
clinically more severe cases of IM (5) and contracts slowly as symptoms resolve,
generating a memory population of resting EBV-speciﬁc cells. Some memory cells
reexpress the CCR7 lymphoid homing marker, facilitating entry into tonsillar tissue and,
ultimately, the establishment of a tissue-resident memory population at this site (17,
18). There is also a comparatively weak (median, 2-fold) expansion of circulating
natural killer (NK) cell numbers in patients during the acute phase of IM, reﬂecting an
increase in cells whose phenotype (CD56dim NKG2A KIR) is intermediate between
the phenotypes of the less mature (CD56bright NKG2A KIR) and more mature
(CD56dim NKG2A KIR) subsets of NK cells present in blood (19–21). At the same time,
circulating dendritic cells of the myeloid (mDC) and, especially, the plasmacytoid (pDC)
subsets are reduced in number (20, 22). Finally, the levels of a range of antiviral and/or
proinﬂammatory cytokines and chemokines are reported to be elevated in the plasma
of IM patients, including beta interferon (IFN-), IFN-, interleukin-1 (IL-1), IL-6, IL-10,
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IL-12, IL-18, tumor necrosis factor alpha (TNF-), monokine induced by IFN- (MIG;
CXCL9), and IFN--induced protein 10 (IP-10; CXCL10) (23–26). Since many of these
cytokines and chemokines can be produced by multiple different cell types, it is difﬁcult
to say whether they derive from infected cells per se or from cells activated as part of
the immune response to infection.
The factors determining whether primary EBV infection is asymptomatic or presents
as IM are poorly understood. Clearly, the age at which the virus is acquired is important.
In that context, the greater risk of IM among adolescents and young adults than among
children has been variously ascribed to their greater chance of acquiring a high initial
virus dose by kissing (14), to the diminishing competence with age of early NK cell
control over new virus acquisition (19), and to the increasing breadth with age of T cell
memory, such that responses to a new agent may be inﬂated by cross-reactive
recognition from previously primed speciﬁcities (27). That said, the effect of age is not
absolute because classical IM is occasionally seen in pediatric cohorts (13, 19) and may
indeed be underrecognized there. Furthermore, epidemiologic studies have found a
greater concordance of the incidence of IM among monozygotic twins than among
dizygotic twins and ﬁrst-degree relatives, strongly implying a genetic element to the
risk of IM that is superimposed upon environmental inﬂuences (28, 29).
A major barrier to progress in this ﬁeld is our almost complete ignorance of the
virologic and immunologic events that occur in asymptomatic primary infection. Some
early studies attempted to address these issues in pediatric cohorts but were largely
limited to serologic screening or to the limited cellular immunologic assays available at
that time (30–32). Several more recent reports have monitored EBV acquisition in
African children but mainly in circumstances not only in which it was difﬁcult to assess
symptomatology but also in which confounding factors affecting immune competence,
notably, coinfection with HIV and/or the malaria parasite, appeared to have predis-
posed the individuals to the high EBV loads observed (33–36). There are many differ-
ences, therefore, between such complex scenarios and clinically silent EBV acquisition
in the nonimmunocompromised host, particularly that which occurs covertly in young
adults in the developed world. Only one previous study, based in Australia, focused on
asymptomatic primary infection in these circumstances (37). During prospective screen-
ing of volunteers for an early EBV vaccine trial, Silins et al. (37) serendipitously identiﬁed
four healthy anti-VCA IgM-positive (IgM), anti-VCA IgG-positive (IgG) or IgG-negative
(IgG), and anti-EBNA1 IgG individuals, two of whom also had EBV genome loads in
their blood like those seen in patients during the acute phase of IM. Although they
were not analyzed for EBV-speciﬁc T cell or NK cell responses, all four asymptomatic
seroconverters had peripheral blood mononuclear cell (PBMC) counts in the normal
range, and only one showed by T cell receptor V analysis evidence of clonal T cell
expansions like those that occur in patients with IM (37). The present study set out to
identify more such individuals, in this case, within a cohort of more than 400 medical
students who volunteered blood samples at the beginning of their course of university
study and, in some cases, annually over the following 4 years. All were monitored for
serologic status with respect to two herpesviruses, EBV and cytomegalovirus (CMV), and
for the EBV load in PBMCs. Overall, using a combination of serologic and virologic
parameters, six subjects were identiﬁed to be likely undergoing asymptomatic primary
infection with EBV at the time that a blood sample was taken; additional blood samples
allowed prospective studies in ﬁve of these cases.
RESULTS
Identifying cases of asymptomatic primary infection. A total of 448 medical
school entrants, all in good health and with no recent history of infectious disease,
volunteered to provide an initial blood sample. Of these, 278 (62%) were found to be
anti-VCA IgG, suggestive of an already established EBV carrier state. Viral DNA was
detected in the majority of but not all seropositive cases (Fig. 1); this reﬂects the
limitation of the assay when applied to DNA from 6  105 PBMCs (36), since in our
hands almost all seropositive individuals are detectably EBV genome positive in the
Asymptomatic Primary EBV Infection Journal of Virology
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same assay using DNA from 6  105 puriﬁed peripheral blood B cells (10). As seen
before among virus carriers in the UK population (10, 36), viral load values were spread
across a very wide (104-fold) range (Fig. 1). Indeed, that range slightly overlapped the
range of viral loads seen in patients during the acute phase of IM, though the median
value for patients during the acute phase of IM is about 70-fold higher than the median
for those in the virus carrier state.
During the analysis of these initial blood samples or subsequently, during annual
follow-ups, a combination of viral load assays and serologic screening identiﬁed six
individuals (designated asymptomatic [AS] individuals AS1 to AS6) who had, fortu-
itously, been sampled while undergoing an asymptomatic primary infection. Four cases
came to light through being EBV genome positive in the viral load assay yet serolog-
ically anti-VCA IgG. Further antibody assays of the plasma samples taken at this time
showed that two of these individuals (AS1 and AS5) were anti-VCA IgM and anti-
EBNA1 IgG at the time, while the other two (AS3 and AS4) were still seronegative even
for anti-VCA IgM. Interestingly, all four individuals had high to very high EBV genome
loads in the blood (770 to 15,600 genomes per 106 PBMCs) but remained asymptomatic
in the weeks after the sample was taken. All four were studied prospectively either
through the collection of additional voluntary blood samples or through the collection
of samples biannually.
To search for other examples of occult primary infection, we retrospectively
screened 248 plasma samples from the above-described anti-VCA IgG cohort and
looked for cases with an anti-VCA IgM, anti-EBNA1 IgG proﬁle. Interestingly, 17
samples were anti-EBNA1 IgG, but of these, 15 were also anti-VCA IgM negative
(IgM). We infer that these 15 anti-VCA IgM, anti-VCA IgG, anti-EBNA1 IgG cases
(EBV load range, 26 to 4,536 genomes per 106 PBMCs; median value, 312 genomes per
106 PBMCs) reﬂected either recent but not current primary infections or the small
fraction of virus carriers (estimated to be about 3%) who remain anti-EBNA1 IgG in the
longer term (38). More importantly, we identiﬁed two individuals with an anti-VCA
IgM, anti-EBNA1 IgG proﬁle indicative of primary infection, and both of these
individuals remained well in the weeks following collection of the key blood sample.
FIG 1 EBV genome loads in long-term virus carriers and cases of primary infection. Viral loads are
reported as the number of EBV genome copies per 106 PBMCs for 276 anti-VCA IgG virus carriers, six
individuals with asymptomatic primary infection (AS1 to AS6) from the same student cohort, and 21
patients during the acute phase IM included for reference. Median viral loads (horizontal bars) for the 232
of 276 anti-VCA IgG virus carriers with detectable EBV DNA loads, for AS1 to AS6, and for the 21 IM
patients were 103, 6,190, and 7,350 EBV genome copies per 106 PBMCs, respectively. Data points below
the dotted line identify the 44 anti-VCA IgG virus carriers who had undetectable EBV loads. Not shown
are data from 166 anti-VCA IgG individuals in the same student cohort; all 166 had, as expected,
undetectable viral loads.
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One individual, AS2, also had a very high viral load (11,350 genomes per 106 PBMCs)
and, because additional biannual samples were available, could be studied prospec-
tively. The other individual, AS6, who had only a relatively low viral load (148 genomes
per 106 PBMCs), did not give additional samples and our observations are limited to just
the one blood sample. Figure 1 compares the viral load data for all six AS cases at the
time of asymptomatic infection with the values seen in long-term virus carriers (anti-
VCA IgG) and in patients during the acute phase of IM; the viral loads seen in
individuals AS1 to AS6 were signiﬁcantly higher than those seen in individuals in the
carrier state and in three cases were well within the range for patients during the acute
phase of IM.
For comparison, the same serologic assays were used to screen 21 patients during
the acute phase of IM, whose EBV loads are also included in Fig. 1; all 21 were anti-VCA
IgM, and 14 were already anti-VCA IgG, whereas all but 1 were anti-EBNA1 IgG
(data not shown). Note, therefore, that the serological proﬁles in four of our asymp-
tomatic cases (AS1, AS2, AS5, and AS6, who were anti-VCA IgM, anti-VCA IgG or
IgG, and anti-EBNA1 IgG) resemble those typically seen in patients during the acute
phase of IM. In contrast, the proﬁle seen in the two other cases (AS3 and AS4, who were
anti-VCA IgM, anti-VCA IgG, and anti-EBNA1 IgG) is atypical and implies that blood
samples were collected these individuals at an earlier stage of infection, before the
development of an IgM response. We also determined the CMV serostatus of the AS
cohort and their acute IM comparators, given the possibility that preexisting CMV
carriage might inﬂuence the course of primary EBV infection (39, 40). All six AS
individuals were CMV seronegative at the time of EBV acquisition, and the ﬁve pro-
spectively studied cases remained so throughout the whole study period. The majority
(18/21) of IM cases were, likewise, CMV seronegative at the time of acute IM.
Prospective studies of AS1 to AS5: viral load, antibody, and T cell responses.
AS1 gave samples on four occasions, initially in October 2007 and then again 5, 17, and
55 months after that date. This individual was identiﬁed to have a very high viral load
(15,600 genomes per 106 PBMCs) at the time of collection of the ﬁrst blood sample and
a serological picture associated with primary infection, i.e., anti-VCA IgM, anti-VCA
IgG, and anti-EBNA1 IgG (Table 1). Surprisingly, the viral load in blood was still high
at 5 months, by which time both anti-VCA IgG and anti-EBNA1 IgG antibody responses
had developed, whereas by later times, the viral load in blood had fallen to a stable
level (albeit at the high end of the virus carrier range) and the serologic picture was that
of a long-term virus carrier, i.e., anti-VCA IgM, anti-VCA IgG, and anti-EBNA1 IgG. In
contrast to the situation typically seen in patients during the acute phase of IM, AS1’s
lymphocyte count was not raised at the time of primary infection, and there was no
dramatic expansion of CD8 T cells. However, the 30% CD8 T cell representation
among the lymphocyte population was higher than that seen in blood samples
collected from this individual at later times. Furthermore, almost 40% of the circulating
CD8 T cells in the blood sample collected at the time of primary infection had an
activated CD38 HLA-DR phenotype, suggesting that a mild expansion had occurred.
Since AS1 was HLA-B*0702 positive, this allowed the initial and subsequent blood
samples to be examined for EBV-speciﬁc CD8 T cells using tetramers for three
EBV-coded B*0702 -restricted epitopes, two lytic (RPR, TPS) and one latent (RPP), here
listed in their typically observed order of dominance (RPR  RPP  TPS) (epitopes are
designated by their initial three residues; see Materials and Methods for the complete
sequences of the epitopes). More than 6% of all CD8 T cells had an RPR-speciﬁc
response at the time of primary infection (Fig. 2; Table 1), and just as seen for
EBV-speciﬁc effectors during the acute phase of IM (15, 16), the great majority of these
RPR-speciﬁc cells were in the CD45RA CCR7 subset and had an activated CD38
HLA-DR phenotype with the associated downregulation of Bcl2 (Fig. 2). Overall,
therefore, about 14% of the CD8 T cell activation that occurred during primary
infection of AS1 could be explained by a response to this one B*0702-restricted epitope.
Five months later, the general CD8 T cell activation had largely resolved and the RPR
epitope response had contracted to a lower level with a loss of activation markers
Asymptomatic Primary EBV Infection Journal of Virology
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(Fig. 2; Table 1). By that time, responses to the subdominant RPP and TPS epitopes had
developed, with the latter still having remnants of an activated phenotype (Table 1).
Subsequent blood samples showed a further slow fall in the size of all three B*0702-
restricted epitope responses and a complete loss of activation markers.
AS2 was EBV negative by both viral load and serology at the time that the ﬁrst blood
sample was collected in October 2009 but 2 years later was found to have a very high
viral load (11,350 genomes per 106 PBMCs) and an anti-VCA IgM, anti-VCA IgG,
anti-EBNA1 IgG antibody proﬁle typical of that seen during a primary infection (Table
1). When AS2 was sampled a further 2 years on, the viral load had fallen to a value just
above the median for normal carriers and the serological picture, anti-VCA IgM,
anti-VCA IgG, anti-EBNA1 IgG, was typical of that for individuals in the long-term
carrier state. In this case, the lymphocyte count at the time of primary infection was
slightly raised (by a factor of 1.5- to 1.8-fold) over earlier and later values. Furthermore,
the percentage of CD8 T cell representation in the lymphocyte population was
increased almost 2-fold, 45% of those CD8 T cells were activated, and at least some
of those T cells were EBV speciﬁc (Table 1). Thus, tetramer staining identiﬁed a highly
activated (CD38 HLA-DR Bcl2low) CD8 T cell response to the HLA-A*0201-restricted
EBV lytic cycle epitope YVL (Fig. 3). These YVL-speciﬁc cells made up 2.5% of all CD8
T cells in the blood at the time and 5% of the activated population. Two years later,
YVL-speciﬁc cells were detectable in lower numbers and had lost their activation
markers. During primary infection, the YVL response was also accompanied by smaller,
but similarly activated, responses to two other A*0201-restricted lytic epitopes, GLC and
LLI (Table 1); these again entered memory as smaller populations. No detectable
response to CLG, a weak A*0201-restricted latent cycle epitope, ever developed.
Corresponding ﬁndings for two further individuals, AS3 and AS4, are summarized in
Table 2. These were distinct from the cases described above, in that both were
TABLE 1 Longitudinal viral loads, CD8 responses, and serological proﬁles of donors AS1 and AS2
Donora
Time
(mo)b
EBV
loadc
Lymphocyte
count
(106/ml)
% CD8
cellsd
% activated
CD8 cellse
EBV CD8 responses EBV serology
EBV
tetramer
% tetramer-
positive CD8
cells
% activated
tetramer-positive
CD8 cells
EBV VCA
IgM titer
EBV VCA
IgG titer
EBNA1 IgG
index value
AS1 0 15,600 1.3 30 39.0 RPR 6.41 85.0 1/20 Negative Negative
RPP 0 0
TPS 0 0
5 6,020 1.7 25 2.1 RPR 0.92 0.4 1/20 1/320 3.9
RPP 0.47 5.9
TPS 0.20 21.6
17 847 3.4 22 0.5 RPR 0.56 0.8 Negative 1/320 16.3
RPP 0.34 0
TPS 0.14 9.7
55 140 1.6 18 0.4 RPR 0.11 0 Negative 1/320 12.8
RPP 0.08 0
TPS 0.06 0
AS2 27 0 2.3 27 1.6 YVL 0 0 Negative Negative Negative
GLC 0 0
LLI 0 0
CLG 0 0
0 11,350 4.1 46 45.0 YVL 1.13 96.0 1/5 1/80 Negative
GLC 0.38 94.0
LLI 0.09 72.0
CLG 0 0
25 350 2.8 27 0.5 YVL 0.07 3.1 Negative 1/320 14.5
GLC 0.09 3.9
LLI 0.02 0
CLG 0 0
aDonor HLA types: for AS1, A1, A3, B7, and B13; for AS2, A2, A11, B40, and B44.
bTime (in months) since primary infection.
cNumber of EBV genome copies per 106 PBMCs.
dPercentage of CD8 cells among total lymphocytes.
ePercentage of HLA-DR CD38 CD8 cells among total CD8 cells.
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identiﬁed to have viral loads that were moderately high (770 and 1,030 genomes per
106 PBMCs, respectively) yet at a time when both were still anti-VCA IgM, anti-VCA
IgG, anti-EBNA1 IgG. This implies that these two individuals had been caught slightly
earlier in the course of infection (relative to AS1 and AS2), although, clearly, EBV had
already entered the circulating B cell pool. At this time, AS3 (HLA-A*0201 and B*0702
positive) showed no evidence of raised lymphocyte counts, of any expansion or
activation in the CD8 T cell pool, or of any A*0201 or B*0702 EBV epitope reactivity
(Table 2). A T cell response did subsequently occur, however, since in blood samples
taken 2 and 4 years later, tetramer staining detected small nonactivated memory
populations speciﬁc for several A*0201- and B*0702-restricted epitopes; the same blood
samples taken at later times also conﬁrmed that the EBV load had fallen, eventually to
below detectable levels, and conversion to a typical virus carrier serostatus (anti-VCA
IgM, anti-VCA IgG, anti-EBNA1 IgG). In the case of AS4 (HLA-B*0702 positive), total
lymphocyte and CD8 T cell numbers were likewise unchanged at the time of primary
infection relative to those seen in earlier and later blood samples, and there was
minimal activation of the general CD8 T cell pool. Interestingly, however, tetramer
FIG 2 Longitudinal analysis of the B*0701-restricted RPR lytic epitope response in donor AS1. PBMCs were obtained from
donor AS1 at the time of asymptomatic infection (AS1.1) and again 5, 17, and 55 months later (AS1.2, AS1.3, and AS1.5,
respectively) and screened for responses against the B*0701-restricted RPR lytic epitope derived from BaRF1. The left-hand
column shows the CD8/tetramer staining proﬁles of the CD3 T cell population. The remaining plots show the phenotypic
proﬁles of the whole CD8 T cell population (gray dots) and of the RPR-speciﬁc CD8 T cells (red dots) after costaining
for HLA-DR and CD38, for Bcl2 and the RPR tetramer, and for CCR7 and CD45RA. Black and red numbers indicate the
percent distribution of total CD3 T cells and of RPR-speciﬁc cells across the four quadrants, respectively.
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staining did detect a small population of cells speciﬁc for the B*0702-restricted RPR
epitope, and 35% of these were activated. Responses to the subdominant B*0702-
restricted epitopes RPP and TYS were not yet present, but 2 years later, all three
reactivities were detectable in memory; by this time, the viral load in PBMCs had fallen
below detectable levels and the serologic picture was typical of that of a long-term
virus carrier (Table 2).
Donor AS5 was sampled on 5 occasions, initially in November 2007 and then again
3, 16, 26, and 54 months after that date. At the time of collection of the ﬁrst blood
sample, this individual (like AS1) was identiﬁed to have a very high viral load (13,450
genomes per 106 PBMCs) and a serologic picture (anti-VCA IgM, anti-VCA IgG,
anti-EBNA1 IgG) associated with primary infection (Table 3). In this case, the viral load
in the blood had fallen well into the normal range for carriers within 3 months,
remained at that level at 16 months, and then became undetectable at later blood
collection times. However, the serologic proﬁle was slow to change; AS5 still remained
anti-VCA IgM, anti-VCA IgG, anti-EBNA1 IgG at 3 months, had become anti-VCA
IgM, anti-VCA IgG, anti-EBNA1 IgG at 16 months, and did not acquire the typical
anti-VCA IgM, anti-VCA IgG, anti-EBNA1 IgG carrier proﬁle until 26 months. Inter-
estingly, the T cell response was also slow to develop (Table 3). There was no sign of
the expansion or activation of the circulating CD8 T cell population either at the time
of primary infection or 3 months later. Total lymphocyte counts were similar at these
times but then increased to a higher level that was maintained at the last three blood
collection times, though without any change in the percentage of CD8 T cells. As AS5
was HLA-A*0201 positive, we stained successive samples using A*0201 tetramers with
relevant EBV epitopes. Responses to the lytic epitopes GLC (Fig. 4), YVL, and LLI were
FIG 3 Longitudinal analysis of the A*0201-restricted YVL lytic epitope response in donor AS2. PBMCs were obtained from
donor AS2 27 months before infection (AS2.1), at the time of asymptomatic infection (AS2.3), and again 25 months later
(AS2.5) and screened for responses against the A*0201-restricted YVL lytic epitope from BRLF1. The left-hand column
shows the CD8 tetramer staining proﬁles of the CD3 T cell population. The remaining plots show the phenotypic proﬁles
of the whole CD8 T cell population (gray dots) and of the YVL-speciﬁc CD8 T cells (red dots) after costaining for HLA-DR
and CD38, for Bcl2 and the YVL tetramer, and for CCR7 and CD45RA. Black and red numbers indicate the percent
distribution of total CD3 T cells and of YVL-speciﬁc cells across the four quadrants, respectively.
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absent in the ﬁrst two blood samples collected but were ﬁrst detected at 16 months
postinfection as small populations still bearing some residual evidence of an activated
phenotype (Table 3). Their numbers had fallen at 26 months, by which time a partly
activated response to the subdominant latent epitope CLG (Fig. 4) was also in evidence,
and the responses to all four epitopes had assumed typical long-term memory levels by
the time of collection of the last blood sample.
To allow comparison of these individuals with asymptomatic EBV infections and
individuals with classical IM, we selected four IM patients (IM221, IM232, IM253, and
IM265) who were either HLA-A*0201 or HLA-B*0702 positive and from whom samples
obtained during the acute phase and follow-up were available for retrospective anal-
ysis. These samples were assayed alongside the samples from individuals with symp-
tomatic infection using the same reagents, and the results are summarized in Table 4.
At the time of the acute phase of IM, all four patients had high viral loads (1,270 to
21,650 genome copies/ml), while the three from whom acute-phase serum samples
were available had an antibody proﬁle consistent with that seen during primary
infection (anti-VCA IgM, anti-VCA IgG, anti-EBNA1 IgG). All four had elevated
lymphocyte counts (3.3 106 to 8.8 106 cells/ml) with a high percentage (60 to 76%)
of CD8 T cells and with 77 to 95% of those CD8 T cells having an activated
phenotype. In blood samples collected later, the viral load fell (in three of four cases),
the antibody proﬁle had become anti-VCA IgM, anti-VCA IgG, anti-EBNA1 IgG, and
TABLE 2 Longitudinal viral loads, CD8 responses, and serological proﬁles of donors AS3 and AS4
Donora
Time
(mo)b
EBV
loadc
Lymphocyte
count
(106/ml)
% CD8
cellsd
% activated
CD8 cellse
EBV CD8 responses EBV serology
EBV
tetramer
% tetramer-
positive CD8
cells
% activated
tetramer-positive
CD8 cells
EBV VCA
IgM titer
EBV VCA
IgG titer
EBNA1 IgG
index value
AS3 0 770 1.9 18 0.5 RPR 0 0 Negative Negative Negative
TPS 0 0
RPP 0 0
YVL 0 0
GLC 0 0
LLI 0 0
CLG 0 0
27 420 1.9 21 1.0 RPR 0.26 0 Negative 1/40 2.8
TPS 0.05 0
RPP 0.05 0
YVL 0.06 0
GLC 0.06 7.7
LLI 0 0
CLG 0 0
51 0 1.8 24 0.2 RPR 0.12 0 Negative 1/40 5.1
TPS 0.01 0
RPP 0.02 0
YVL 0.03 0
GLC 0.06 0
LLI 0 0
CLG 0 0
AS4 9 0 1.9 24 0.4 RPR 0.00 0.0 Negative Negative Negative
TPS 0.00 0.0
RPP 0.00 0.0
0 1,030 1.8 25 1.9 RPR 0.33 35.3 Negative Negative Negative
TPS 0.00 0.0
RPP 0.00 0.0
26 0 2.0 26 1.2 RPR 0.07 0.0 Negative 1/80 30.1
TPS 0.01 0.0
RPP 0.50 1.5
aDonor HLA types: for AS3, A1, A2, B7, and B57; for AS4, A24, A25, B7, and B18.
bTime (in months) since primary infection.
cNumber of EBV genome copies per 106 PBMCs.
dPercentage of CD8 cells among total lymphocytes.
ePercentage of HLA-DR CD38 CD8 cells among total CD8 cells.
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the lymphocyte count normalized, as did the percentage of CD8 T cells and the CD8
activation phenotype. Staining with the above-described panel of A*0201 and B*0702
tetramers showed activated CD8 responses to the relevant epitopes during the acute
phase, followed by the resolution of these activated responses down to resting memory
levels (Table 4). Note that in the acute phase these particular epitope-speciﬁc responses
were relatively small (comprising only up to 7% of total CD8 T cells), reﬂecting the fact
that neither HLA-A*0201 nor B*0702 is a strong EBV response allele and is frequently
outcompeted by more dominant restricting alleles in the genotype, most likely by
HLA-B*0801 in the cases of IM221 and IM232 (15, 16).
The data in Fig. 5 show how the percentage of CD8 T cells within the lymphocyte
population changed over time for these IM patients and for asymptomatic cases AS1 to
AS5; red dotted lines denote the time of primary infection. The scatter plots (Fig. 5,
right) show for each of the IM patients and for AS1 to AS5 the ratio of the percentage
of CD8 T cells seen in primary infection versus the mean percentage seen in blood
samples taken from the same individual 6 months postinfection. The signiﬁcant
difference between the two sets of results makes it clear that the gross expansion of
CD8 T cells typically seen in patients during the acute phase of IM was not observed
during asymptomatic infection. Note that a similar picture emerged from the other case
of asymptomatic primary infection, AS6, from whom only the primary infection blood
sample was available. There was again no obvious lymphocytosis in the blood, and the
CD8 T cell population constituted only 25% lymphocytes and completely lacked
activation markers (data not shown).
Prospective studies of AS1 to AS5: NK cell responses. Given recent reports of
mild NK cell expansion (19) accompanied by differentiation of immature CD56bright cells
to an intermediate CD56dim NKG2A KIR phenotype (19–21) in patients during the
acute phase of IM, we established staining protocols that could identify the total NK cell
population and the relevant NK cell subsets (Fig. 6A). We then used these protocols to
analyze the sequential samples from patients during the acute phase of IM and AS
TABLE 3 Longitudinal viral loads, CD8 responses, and serological proﬁles of donor AS5a
Time
(mo)b
EBV
loadc
Lymphocyte
count
(106/ml)
% CD8
cellsd
% activated
CD8 cellse
EBV CD8 responses EBV serology
EBV
tetramer
% tetramer-
positive CD8
cells
% activated
tetramer-positive
CD8 cells
EBV VCA
IgM titer
EBV VCA
IgG titer
EBNA1 IgG
index value
0 13,450 1.4 26 0.5 YVL 0 0 1/20 Negative Negative
GLC 0 0
LLI 0 0
CLG 0 0
3 180 1.4 31 0.3 YVL 0 0 1/10 Negative Negative
GLC 0 0
LLI 0 0
CLG 0 0
16 160 3.9 32 2.8 YVL 0.69 6.9 Negative 1/160 Negative
GLC 0.73 9.1
LLI 0.73 4.3
CLG 0 0
26 0 3.3 32 1.3 YVL 0.26 5.0 Negative 1/160 2.9
GLC 0.46 2.1
LLI 0.20 1.5
CLG 0.06 21.0
54 0 3.4 30 0.6 YVL 0.23 0 Negative 1/160 1.7
GLC 0.31 0
LLI 0.16 0
CLG 0.04 0
aDonor HLA type: A2, A31, B40, and B44.
bTime (in months) since primary infection.
cNumber of EBV genome copies per 106 PBMCs.
dPercentage of CD8 cells among total lymphocytes.
ePercentage of HLA-DR CD38 CD8 cells among total CD8 cells.
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donors. Figure 6B shows the individual data and summary plots in a format that follows
the layout introduced in Fig. 5.
Studying the PBMCs collected from ﬁve prospectively studied IM patients (including
the four used for tetramer staining as described above) during and after the acute
phase conﬁrmed the recently reported trends (19–21). Note that the size of the CD56
NK cell population, when expressed as a percentage of total lymphocytes, was typically
about 2-fold lower in blood samples collected during the acute phase of IM than in
blood samples collected later, after the acute phase of IM; however, this reduced
percentage during the acute phase is a side effect of the dominant CD8 T cell
expansion and does not reﬂect a real fall in numbers. Indeed, when allowance is made
for the 3- to 4-fold increase in total PBMCs seen during IM, absolute NK cell numbers
were 1.5- to 2-fold higher during the acute phase. Staining with the NK cell subset
markers further showed that the proportion of CD56bright cells within the NK cell
population was lower during the acute phase than after the acute phase of IM, while
that of CD56dim NKG2A KIR cells was higher (Fig. 6B), consistent with a preferential
expansion of the latter subset during IM (19–21).
In contrast, corresponding data on sequential blood samples from donors AS1 to
AS5 showed, in most cases, no evidence of elevated CD56 NK cell representation
within the lymphocyte population during primary infection and no change in the
relative representation of the CD56bright and CD56dim NKG2A KIR subsets (Fig. 6B).
The one partial exception was AS3, in whom the percentage of CD56 cells within the
(nonexpanded) PBMC pool at the time of primary infection was unusually high, whereas
FIG 4 Longitudinal analysis of the delayed EBV lytic epitope responses in donor AS5. PBMCs were obtained from donor AS5 at the time of asymptomatic
infection (AS5.1) and again 3, 16, 26, and 54 months later (AS5.2, AS5.3, AS5.4, and AS5.5, respectively) and screened for responses against the A*0201-restricted
GLC lytic epitope from BMLF1 (A) and the A*0201-restricted CLG latent epitope from LMP2 (B). In each case, the left-hand column shows the CD8 tetramer
staining proﬁles of the CD3 T cell population. The remaining plots show the phenotypic proﬁles of the whole CD8 T cell population (gray dots) and of the
tetramer-speciﬁc CD8 T cells after costaining for HLA-DR and CD38, for Bcl2 and the relevant tetramer, and for CCR7 and CD45RA. Black and red numbers
indicate the percent distribution of total CD3 T cells and of GLC- or CLG-speciﬁc cells across the four quadrants, respectively.
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more typical values were seen in later blood samples. However, this apparent expan-
sion occurred without enrichment of the CD56dim NKG2A KIR NK subset (Fig. 6B).
Furthermore, in their blood samples collected at the time of primary infection, the AS
donors showed no evidence of NK cell activation using two markers, increased HLA-
DR expression and the loss of Bcl2, that, in our hands, were typically seen in the NK
TABLE 4 Longitudinal viral loads, CD8 responses, and serological proﬁles of acute IM cases
Donora
Time
(mo)b
EBV
loadc
Lymphocyte
count
(106/ml)
% CD8
cellsd
% activated
CD8 cellse
EBV CD8 responses EBV serologyf
EBV
tetramer
% tetramer-
positive CD8
cells
% activated
tetramer-positive
CD8 cells
EBV IgM
VCA titer
EBV IgG
VCA titer
IgG EBNA1
index value
IM221 0 1,270 3.3 76 83.1 YVL 2.10 97.4 1/40 1/80 Negative
GLC 0.07 57.6
LLI 1.92 90.9
CLG 0 0
19 640 1.1 35 10.8 YVL 0.46 16.1 Negative 1/160 19.4
GLC 0.20 7.1
LLI 0.46 11.0
CLG 0.13 17.4
29 130 0.7 32 8.2 YVL 0.54 14.5 Negative 1/80 16.8
GLC 0.26 17.4
LLI 0.29 17.2
CLG 0.06 10.5
IM232 0 19,290 8.8 74 80.3 YVL 0.05 87.2 Not done
GLC 0.34 96.4
LLI 0 0
CLG 0 0
15 49 1.8 29 0.9 YVL 0.06 0 Negative 1/160 1.7
GLC 1.80 1.8
LLI 0.02 0
CLG 0.03 0
24 111 1.5 25 0.6 YVL 0.05 7.1 Negative 1/640 2.1
GLC 0.75 1.5
LLI 0 0
CLG 0 0
76 0 2.5 28 0.4 YVL 0.07 0 Negative 1/640 3.5
GLC 1.36 0.3
LLI 0.01 0
CLG 0.03 0
IM253 0 5,010 5.0 76 95.3 RPR 7.07 98.7 1/320 1/160 Negative
TPS 0 0
RPP 0.44 99.5
7 8,740 0.9 37 6.1 RPR 1.77 2.3 Negative 1/160 16.0
TPS 0.74 26.3
RPP 2.23 4.1
19 5,800 0.7 28 6.9 RPR 1.03 2.7 Negative 1/80 31.5
TPS 0.55 8.2
RPP 1.39 4.1
IM265 0 21,650 3.3 60 76.9 RPR 3.62 91.5 1/40 1/80 Negative
TPS 0 0
RPP 1.21 99.5
5 5,420 0.6 26 2.2 RPR 0.70 2.7 Negative 1/80 4.8
TPS 0.25 18.5
RPP 0.30 17.7
19 1,310 1.2 27 1.4 RPR 0.23 4.8 Negative 1/160 21.0
TPS 0.24 3.1
RPP 0.29 7.7
aDonor HLA types: for IM221, A1, A2, B8, and B44; for IM232, A2, A3, B8, and B27; for IM253, A3, A24, B7, and B37; for IM265, A23, A26, B7, and B44.
bTime (in months) since primary infection.
cNumber of EBV genome copies per 106 PBMCs.
dPercentage of CD8 cells among total lymphocytes.
ePercentage of HLA-DR CD38 CD8 cells among total CD8 cells.
fIM221 and IM253 were CMV seronegative, IM265 was CMV seropositive, and IM232 was not tested for CMV.
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cells of patients during the acute phase of IM (data not shown). The summary scatter
plots (Fig. 6B, center right and bottom right) show the percentage of CD56bright and
CD56dim NKG2A KIR NK cell subsets at the time of primary infection relative to that
seen in later blood samples from the same individuals. The scatter plots for patients
during the acute phase of IM and the AS individuals were signiﬁcantly different,
reﬂecting the absence of a detectable NK cell response like that seen in patients during
the acute phase of IM at the time that samples were collected from the ﬁve asymp-
tomatic individuals with primary infections.
Prospective studies of AS1 to AS5: DC frequencies and plasma cytokines. The
ﬁnal sets of experiments asked to what extent two other hematological features of the
acute phase of IM were detectable in individuals with asymptomatic primary infection,
namely, the almost complete loss of pDCs and the partial loss of mDCs recently
reported to occur in the blood of patients with IM (20, 22) and the well-documented
increase in the circulating levels of various antiviral and/or proinﬂammatory cytokines
and chemokines during the acute phase of disease (23–26).
To examine DC populations, we established a staining protocol that identiﬁes both
pDCs (deﬁned as live lineage-negative HLA-DR CD11clow CD123high cells) and mDCs
(deﬁned as live lineage-negative HLA-DR CD11chigh CD123 cells) (Fig. 7A). Applying
this to prospective blood samples from our ﬁve reference IM patients, we found that
the percentage of pDCs and mDCs was very low (Fig. 7B, left). This was particularly the
case for pDCs, with a median value of 0.062% mononuclear cells, 8-fold lower than the
levels reached after the acute phase of IM, while mDCs underwent a similar but less
marked decrease, with a median value of 0.065%, 4.5-fold lower than the levels
observed after the acute phase of IM. A change of this magnitude cannot be wholly
explained by the diluting effect of CD8 T cell expansion in the blood of patients
during the acute phase of IM but must reﬂect an actual depletion of the circulating pDC
and mDC population. Corresponding data for AS1 to AS5 revealed a mixed picture (Fig.
7B). Both AS1 and AS2, the two individuals with asymptomatic infections characterized
by high viral loads and an activated CD8 T cell response, gave results suggestive of
pDC and mDC depletion. In contrast, the other three asymptomatic infections occurred
without obvious effects on circulating DC numbers. The summary scatter plots (Fig. 7B,
right) illustrate the rather tight patterns of DC depletion seen in patients during the
acute phase of IM relative to the values after the acute phase of IM versus the much
more heterogeneous picture seen in the AS subjects.
Finally, using a Luminex assay, we screened longitudinal plasma samples from the
IM and AS cases for concentrations of 11 cytokines/chemokines reported to be elevated
in patients IM. We found increased levels of IL-18, IP-10, and MIG to be the most
sensitive and consistent indicators of analyte dysregulation in patients during the acute
phase of IM, with peak concentrations being the greatest for MIG and IP-10. Figure 8
shows data from ﬁve IM patients, with the IL-18, MIG, and IP-10 levels present during
the acute phase being much higher than those present in the weeks and months after
the acute phase of IM. The corresponding results for the individual AS subjects are
FIG 5 Longitudinal analysis of CD8 T cells in IM patients and in cases of asymptomatic infection. Shown are the proportions
of CD8 T cells within the lymphocyte population over time for four IM patients (IM221, IM232, IM253, IM265) (left) and for
asymptomatic infection cases AS1 to AS5 (the ﬁve middle graphs). In each case, the time of primary infection is indicated by
the vertical red dotted line. The scatter plots (right) show the ratio of the proportion of CD8 T cells at the time of primary
infection to the mean proportion of CD8 T cells at time points more than 6 months later (1°/recovery) for both the IM and
AS groups.
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shown alongside; the picture was, again, heterogeneous. Both AS1 and AS2 had clear
increases in MIG levels at the time of primary infection, accompanied by a small
elevation of the IL-18 levels above the baseline levels (note the reduced scale for IL-18
and MIG concentrations compared to those seen in IM patients); in addition, AS1
showed an increase in IP-10 levels. In contrast, AS3 and AS4 showed rising levels of all
3 cytokines over time but no clear evidence of changes speciﬁcally linked to EBV
infection. Most interesting were the data from AS5, for whom there was a long delay
between virus acquisition and a virus-speciﬁc T cell response; in this case, increased
FIG 6 Longitudinal analysis of NK cell subsets in IM patients and in cases of asymptomatic infection. (A) Gating strategies for ﬂow cytometric
analysis to identify total NK cells (deﬁned as live lineage-negative CD56 cells), CD56bright cells, CD56dim cells, and CD56dim NKG2A KIR cells
within the lymphocyte population. The percentage of cells in each gate is indicated. The staining shown is for a sample from a representative
asymptomatic subject (AS2) collected 27 months before the detection of viremia. FSC, forward scatter; SSC, side scatter. (B) Longitudinal blood
samples from ﬁve IM patients (IM221, IM225, IM232, IM253, and IM265) and asymptomatic infection cases AS1 to AS5 were analyzed by
multiparameter ﬂow cytometry to determine the percentage of CD56 NK cells within lymphocytes, the percentage of CD56bright NK cells within
the circulating CD56 NK population, and the percentage of NKG2A KIR cells in the CD56dim NK cell population. Combined results for IM
patients and individual results for AS1 to AS5 are displayed as shown in Fig. 5, with the time of primary infection being identiﬁed by a vertical
red dotted line. The scatter plots (right-hand column) show the ratio of the proportion of each subset at the time of primary infection to the mean
proportion at time points more than 6 months later (1°/recovery) for both the IM and AS groups.
Abbott et al. Journal of Virology
November 2017 Volume 91 Issue 21 e00382-17 jvi.asm.org 14
 o
n
 O
ctober 19, 2017 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
levels of MIG and IP-10 coincident with the cellular response and not with infection per
se were observed.
DISCUSSION
Our understanding of primary EBV infection in its usual asymptomatic form is very
limited because of the difﬁculty of studying a clinically silent event. As a result, much
is inferred from the study of IM, a disease which appeared in afﬂuent societies as an
unexpected consequence of delayed primary infection and which, in evolutionary
terms, is a novelty. Whether IM is a legitimate model for the successful control of
primary EBV infection or an artifact of inefﬁcient control remains to be determined. The
fact that not all delayed primary infections are clinically manifest as IM (3–6) affords an
opportunity to address this issue, provided that one can identify asymptomatic cases.
An earlier study (37) serendipitously identiﬁed four IgM anti-VCA-positive individuals
during serologic screening of volunteers for an EBV vaccine trial. In the present work,
we took advantage of a study in which entrants into a UK medical school were screened
annually or biannually throughout their degree course for EBV and CMV status. This
allowed us to identify six individuals undergoing subclinical primary infection with EBV
at one point during their studies; four of these were identiﬁed to be anti-VCA IgM by
serologic screening (as in reference 37), while two were found to be EBV DNA positive
yet still anti-VCA IgM negative (IgM). In two cases (both anti-VCA IgM), we were able
to arrange for the collection of additional blood samples in the months following
infection; in three other cases, we had access only to those samples taken biannually
before or after the event, and in one case, we had only the blood sample collected at
FIG 7 Longitudinal analysis of DC subsets in IM patients and in cases of asymptomatic infection. (A) Gating strategy for ﬂow cytometric
analysis of DC populations to identify total mDCs (deﬁned as live lineage-negative [Lin] HLA-DR CD11chigh CD123 cells) and pDCs
(deﬁned as live lineage-negative HLA-DR CD11clow CD123high cells) withing the mononuclear cell population. The percentage of cells
in each gate is indicated. The staining shown is for a sample from a representative asymptomatic subject (AS2) collected 27 months
before the detection of viremia. (B) Longitudinal blood samples from ﬁve IM patients (IM221, IM225, IM232, IM253, and IM265) and
asymptomatic infection cases AS1 to AS5 were analyzed by multiparameter ﬂow cytometry to determine the percentage of pDCs and
mDCs among circulating mononuclear cells. Combined results for IM patients and individual results for AS1 to AS5 are displayed as
shown in Fig. 5, with the time of primary infection being identiﬁed by a vertical red dotted line. The scatter plots (right) show the ratio
of the proportion of each subset at the time of primary infection to the mean proportion observed at time points more than 6 months
later (1°/recovery) for both the IM and AS groups.
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the time of primary infection. Such constraints are clearly a limitation since changes are
occurring rapidly during primary infection and one’s snapshot of the virus-host inter-
action is highly dependent on the time of sampling. Nevertheless, the present work is
only the second published analysis of asymptomatic EBV acquisition in adulthood and
the only one using a wide range of immunological tools to allow direct comparison
with individuals of a similar age who developed acute IM.
The ﬁrst of several important questions concerned the viral loads in individuals with
asymptomatic infection. Here the message was clear. Three individuals, AS1, AS2, and
AS5, with an EBV antibody proﬁle equivalent to that seen in patients during the acute
phase of IM (anti-VCA IgM, anti-VCA IgG or IgG, anti-EBNA1 IgG) had circulating
EBV genome loads well within the range of those in patients during the acute phase of
IM, whereas a fourth individual, AS6 (anti-VCA IgM, anti-VCA IgG, anti-EBNA1 IgG),
had a relatively low load, although it may be that we had missed an earlier peak of
infection in this particular case. The other two individuals, AS3 and AS4, had loads that
were just below the range of those found in patients with IM; however, the fact that
neither individual had yet mounted a detectable anti-VCA IgM response suggests
that they may have been caught relatively early in the course of infection, with the EBV
load in the blood possibly still rising. These ﬁndings reinforce those in the earlier report
of asymptomatic adult infections, where two of three anti-VCA IgM individuals tested
had elevated viral loads in PBMCs similar to those in patients with IM (37). Together the
two studies make it clear that, while the severity of symptoms in patients during the
acute phase of IM is reported to correlate directly with the viral load in the blood (5),
the viral load per se cannot be the driver of symptoms since most individuals with
asymptomatic infections identiﬁed to date display similarly high loads.
We stress that these elevated EBV loads refer to cell-associated virus genomes and
almost certainly reﬂect the high frequencies of latently infected cells present within the
circulating B cell pool. We could not prove this directly in the present work because the
limited number of blood samples from AS individuals precluded isolation of the B cell
fraction. However, many previous studies in subjects with high PBMC loads, whether
they were IM patients, immunocompromised transplant recipients, or healthy individ-
uals, have shown that EBV is selectively carried in B cells and as a latent, not lytic,
infection (10, 11, 41, 42). This speaks against virus replication as a major contributor
FIG 8 Longitudinal analysis of IL-18, IP-10, and MIG in plasma samples from IM patients and in individuals with asymptomatic
infection. Longitudinal PBMC samples from ﬁve IM patients (IM221, IM225, IM248, IM253, and IM265) and asymptomatic
infection cases AS1 to AS5 were analyzed for the concentrations of IL-18, IP-10, and MIG in plasma. Combined results for IM
patients and individual results for AS1 to AS5 are arranged as shown in Fig. 5, with the time of primary infection being
identiﬁed by a red dotted line. The scatter plots (right) show the ratio of the quantity of each analyte at the time of primary
infection to the mean quantity observed at time points more than 6 months later (1°/recovery) for both the IM and AS groups.
ns, not signiﬁcant.
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either to cell-associated viral loads or, through virus shedding, to cell-free viral DNA in
plasma. In the latter context, even in the most acute cases of IM with huge B cell loads,
viral genomes are only transiently detectable in plasma and are detectable at very low
levels (12, 43). At the same time, it is important to recognize that studies of PBMCs
and/or circulating B cells tell us nothing about the oropharyngeal infection, in partic-
ular, about the level of infectious virus shedding in the throat. We did not take throat
washings in the present work. Recently, however, two prospective studies of EBV-
seronegative students sampled both sites at regular intervals and found that, in those
individuals who subsequently developed IM, virus shedding did not become detectable
until very close to or at the time that symptoms appeared (5, 6), suggesting that there
is little oropharyngeal replication occurring in the long prodromal phase. This rein-
forces the idea that oropharyngeal B cells are the ﬁrst target of orally transmitted virus
and that foci of lytic replication in permissive epithelium are dependent upon seeding
from locally infected B cells. Interestingly, in contrast to the viral load in the blood, the
levels of virus replication in the throats of IM patients bear no relationship to the
severity of symptoms (5); indeed, such discordance is also apparent after the acute
phase of IM, with oral shedding typically remaining high long after the resolution of
symptoms (5, 12, 17).
We next examined aspects of the cell-mediated response in asymptomatic infection.
In their earlier study, Silins et al. (37) found no evidence that their subjects had raised
lymphocyte counts at the time of infection; however, they were unable to look at the
key features affecting the blood picture in patients with IM, namely, CD8 T cell
activation and the induction of a massive EBV antigen-speciﬁc CD8 T cell response (15,
16). In the present work, we found that three of our ﬁve prospectively studied subjects
had an ongoing virus-speciﬁc CD8 response at the time that EBV was ﬁrst detected, and
in two of those individuals (AS1 and AS2), this was coincident with signiﬁcant levels of
activation in the CD8 T cell pool; however, overall CD8 T cell numbers never rose to
the levels seen in patients during the acute phase of IM. In the case of AS1, while the
total lymphocyte counts were not raised at the time of infection, the percentage of
CD8 T cells was higher than that in subsequent blood samples, and almost 40% of
those CD8 T cells were activated. Furthermore, tetramer staining showed that about
15% of that activation could be explained by the response to one EBV lytic cycle
epitope, while a blood sample taken 6 months later revealed a delayed response to two
further epitopes. In the case of AS2, a somewhat larger CD8 T cell expansion sufﬁcient
to cause a detectable (but still 2-fold) increase in total lymphocyte counts was
observed. Some 45% of the expanded CD8 population was activated, and the activated
population contained CD8 T cell responses to three EBV lytic epitopes. Both AS1 and
AS2 therefore showed elements of a CD8 T cell response like that in patients during
the acute phase of IM but in a less exaggerated form. How much of the overall CD8
T cell activation can be ascribed to EBV-speciﬁc cells in such cases remains a moot
point. Some of this may reﬂect bystander activation, as acute EBV infection has been
shown to induce an activated phenotype (though not proliferation) in preexisting
CD8 T cell memory to unrelated viruses (44). However, we anticipate that the
EBV-speciﬁc response is a major contributor because our tetramer assays, focusing on
a small number of epitopes restricted through just one or two HLA alleles, clearly
underestimated the true size of that response.
In contrast to the cases described above, AS3 and ASS4 showed no evidence of any
lymphocytosis or general CD8 T cell expansion/activation in the ﬁrst virus-positive
blood sample. However, since both individuals may have been sampled relatively early
in the course of infection and were not resampled until much later, it may be that a
subsequent expansion occurred and was missed. This remains a possibility, but, at least
in the case of AS4, an EBV-speciﬁc CD8 T cell response was already detectable without
disturbance of the CD8 T pool as a whole. AS3 and AS4 may therefore represent cases
with positions at the other end of the asymptomatic spectrum, i.e., cases where control
of the infection occurs without an obvious impact on the CD8 pool as a whole. Most
interesting was the case of AS5, who, despite already sustaining high EBV loads in the
Asymptomatic Primary EBV Infection Journal of Virology
November 2017 Volume 91 Issue 21 e00382-17 jvi.asm.org 17
 o
n
 O
ctober 19, 2017 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
blood, showed no lymphocytosis, no CD8 expansion/activation, and no detectable
EBV-speciﬁc CD8 response either during the acute phase of infection or in a blood
sample taken 3 months later. It was not until 16 months after the time of collection of
the ﬁrst blood sample that an EBV-speciﬁc CD8 T cell response was detected, at which
time cells reactive to three lytic epitopes were present, and some still had a phenotype
suggesting relatively recent activation. Later blood samples detected the same CD8 T
cell reactivities in memory, and this was joined in the blood sample collected 26
months after the time of collection of the ﬁrst blood sample by a recently activated
response to a subdominant latent epitope. Note that there is a parallel between this
long-delayed T cell response to infection and the same individual’s unusually slow IgG
(i.e., T cell-dependent) antibody response to the virus; thus, AS5 was still anti-VCA IgG
3 months after the primary infection and still anti-EBNA1 IgG after 16 months.
Several lines of evidence both from IM patients (5, 45) and from children with
primary immune deﬁciencies (46, 47) suggest that, besides T cells, the NK cell system
has a role to play in restraining EBV infection. As to the mechanism of control, early
interest came from the ﬁnding that CD56bright NK cells (the dominant NK cell subset in
lymphoid tissues) have the potential to delay EBV-induced B cell transformation in vitro
by producing IFN- (48). However, more recent work studying EBV infection in the
humanized mouse model suggests that NK cells target lytic rather than growth-
transforming latent infections (49). This accords with in vitro evidence that latently
infected B cells become susceptible to NK cell recognition and killing only upon entry
into the lytic cycle (50). Interestingly, the CD56dim NKG2A KIR subset that best
mediates such lytic cycle recognition in vitro is also the subset that is preferentially
expanded in the blood of IM patients (19). This has prompted the hypothesis that NK
cells play an important role early in the host response to primary EBV infection by
controlling lytic virus replication, thereby limiting the amount of infectious virus
entering the B cell system and also reducing the yield of lytic antigens that are the main
drivers of the primary CD8 T cell response (49). By this argument, since IM is a disease
associated with high viral loads and an exaggerated T cell response, it may arise as a
result of impaired NK cell control; conversely, asymptomatic infection would be asso-
ciated with efﬁcient NK cell responses. In the present study of asymptomatically
infected individuals, we therefore extended our analysis to include the circulating NK
cell population and its subsets. One possibility was that, in comparison to the small
expansion in NK cell numbers and slight increase in CD56dim NKG2A KIR represen-
tation reported in IM patients (19), these indicators of an active NK cell response would
be magniﬁed in individuals with asymptomatic infection. Using protocols that con-
ﬁrmed the reported NK cell changes in the blood of IM patients, we found (in at least
four of the ﬁve individuals studied) no clear evidence for expansion either of total NK
cells or of the CD56dim NKG2A KIR subset. The one partial exception was AS3 (one
of the two cases possibly caught early postinfection), in whom the percentage repre-
sentation of total NK cells was increased in the lymphocyte population at the time that
EBV was ﬁrst detected; however, this was not accompanied by any sign of NK cell
activation or a subset shift. Taken overall, our ﬁndings suggest that, contrary to the
prediction made above, asymptomatic infection is not characterized by an NK cell
response that is magniﬁed compared to that seen in IM patients. However, we would
add two caveats to this conclusion. First, it is possible that the key NK cell responses are
only transiently reﬂected in the blood and were simply missed because of the irregular
monitoring of our AS cases, especially in those individuals who (unlike patients during
the acute phase of IM) had not yet become anti-VCA IgM. Second, the composition of
NK populations in the blood does not necessarily reﬂect what is occurring at the
presumed site of NK cell action, in oropharyngeal tissues.
Little is known about EBV’s interaction with other innate immune cell lineages. In
this regard the potential importance of myeloid cells and, in particular, DCs is inter-
esting because the virus genome encodes a unique lytic cycle protein, BARF1, which
blocks colony-stimulating factor 1 (CSF-1), a cytokine promoting myeloid cell prolifer-
ation/function (51). Moreover, in the macaque model with the EBV-related rhesus
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lymphocryptovirus, deletion of the rhesus lymphocryptovirus BARF1 coding sequence
(hence, the loss of BARF1’s immune-evasive effects) led to lower viral loads during
the acute stage of infection (52), implying that the early events of virus infection in
vivo are indeed subject to immune pressure from the myeloid lineage. Reasoning that
the recently described loss of pDCs and mDCs from the blood of patients during the
acute phase of IM (20, 22) might reﬂect active mobilization of such an innate response
toward the site of infection, as observed in other viral systems (53, 54), we asked
whether the same fall in the number of circulating DCs was also detectable in
asymptomatic cases. Interestingly, both AS1 and AS2, the two individuals with asymp-
tomatic infections that had viral loads and T cell response kinetics most like those in
patients during the acute phase of IM, did indeed show lower levels of pDC and mDC
subset representation (as a percentage of all PBMCs) in the blood sample collected at
the time of primary infection compared to those seen in blood samples collected at
later times. In contrast, AS5 showed no signiﬁcant change, even though AS5 had
circulating EBV genome loads as high as those in patients AS1 and AS2 this is at least
consistent with the idea that, in this individual, not only the adaptive immune response
but also parts of the innate immune response were delayed.
The work was then extended to another reported feature of acute IM: the increase
in the levels of several proinﬂammatory cytokines/chemokines in plasma (23–26).
Screening for a range of these candidates, we found that the levels of many were
elevated in some but not all samples from patients during the acute phase of IM; this
likely reﬂects the transient nature of some cytokine/chemokine elevations in patients
during the acute phase of IM, with levels rising and falling at particular times even
within the disease course itself. In contrast, we identiﬁed three markers that appeared
to be less susceptible to such variability, being consistently increased across our panel of
samples from patients during the acute phase of IM: these were IL-18, known to induce
IFN- production (55), and IP-10 and MIG, both of which are induced by IFN- (56). Going
on to study these markers in the individuals with asymptomatic infections, we found some
interesting changes, though the magnitude of change was always less marked than that in
patients during the acute phase of IM. Thus, the blood samples collected from AS1 and AS2
at the time of acute infection showed slight rises in IL-18 levels over those at the baseline
and larger increases in MIG and (for AS1) also in IP-10 levels. In contrast, both AS3 and AS4
showed no such effect, possibly because they were sampled relatively early in the course
of infection. More interestingly, cytokine levels were also not increased in the blood sample
from AS5 with a high viral load collected at the time of acute infection; however, the levels
of both MIG and IP-10 were signiﬁcantly elevated (compared to earlier and later levels) in
the blood sample taken at 16 months, just after the peak of the virus-speciﬁc CD8 T cell
response. This chimes with recent work on the changing transcriptional proﬁle of PBMCs
over the course of IM, where upregulation of IFN- pathway genes strongly correlated with
CD8 T cell expansion rather than other parameters (57). We provisionally conclude that,
for those cytokines/chemokines that are most markedly elevated during primary EBV
infection, the cytokine storm is not a product of the virus infection itself but of the
exaggerated immune response to infection.
In summary, the present study helps to resolve some of the questions that surround
asymptomatic primary infection, notably, with respect to the latent viral load in the
blood, which can be as high as that in patients during the acute phase of IM, and the
cell-mediated immune response, which may be qualitatively similar to that in patients
during the acute phase of IM but never matches its size. However, our observations also
emphasize the need for further, more intense, studies and highlight the challenges that
such studies face. In particular, one does not know the point at which samples from
individuals with asymptomatic infection are directly comparable to those from patients
during the acute phase of IM because the kinetics of infection (virus acquisition,
oropharyngeal replication, entry into the circulating B cell pool) may be different in the
two situations. Furthermore, the present results, albeit from a limited study, strongly
suggest that asymptomatic infections themselves do not follow a uniform kinetic path.
For example, AS1 was similar to IM patients in mounting a prompt CD8 T cell response
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to primary infection followed by a T cell-dependent IgG antibody response to both VCA
and EBNA1; in contrast, in AS5, who was caught with an equally high viral load at the
time of primary infection, the responses were delayed by at least several months.
Intriguingly, these response kinetics did not correlate with the anticipated changes in
the latent viral load; thus, despite mounting a prompt response, AS1 still had a high
viral load in the blood at 6 months postinfection (though it fell to normal levels after
that time), whereas the viral load in AS5 had fallen signiﬁcantly within 3 months in the
apparent absence of any T cell-mediated response.
Interpretation of these ﬁndings is difﬁcult without a proper understanding of the
early events that occur in the oropharynx following oral transmission of the virus (8, 9,
17, 20). Important prospective studies identifying subjects in the 5- to 7-week prodro-
mal phase of IM have shown that high viral loads in both throat washing and blood
samples do not appear until about the time of onset of symptoms (20); the authors
suggest that a slow smoldering infection of the local B cell system may take weeks
before expansion to a magnitude that drives an immune hyperreaction (20). With
respect to that hyperreaction, evidence both from X-linked lymphoproliferative
disease studies (58–60) and from the humanized mouse model (49) strongly
suggest that lytically infected B cells, as opposed to the mucosal epithelium, are the
main drivers of both the NK and highly expanded CD8 T cell responses seen in
patients with IM. The balance between lytic and latent B cell infection is ﬁnely
drawn, and it seems possible that, if the local environment within the oropharynx
favors latency, then the general B cell system might be colonized without putting
the NK and T cell systems on high alert. The inference is that, compared to patients
during the acute phase of IM, asymptomatic infections would be characterized by
lower oropharyngeal replication of the incoming virus and, hence, a lower lytic
antigen load. More broadly, perhaps the most important lesson from this work is
that not all asymptomatic infections necessarily follow the same course; while some
may be like those seen in patients during the acute phase of IM in the timing and
quality of the immune responses, others may be quite different and ultimately
reveal novel mechanisms of host control.
MATERIALS AND METHODS
Study cohort. Initial blood samples were collected from a total of 448 medical students recruited
either between October and December 2007 or between October and December 2009 when
entering their degree course. Subject to consent, follow-up samples were collected in year 2
(February or March), year 3 (December or January), and year 5 (February to May) of their studies.
Additional samples were requested from particular individuals if subsequent assays revealed recent
EBV infection. This study was approved by the West Midlands (Edgbaston) Research Ethics Com-
mittee (REC reference 07/H1208/40), and participants gave written informed consent in accordance
with the Declaration of Helsinki.
Sample collection and preparation. PBMCs were isolated from a 20-ml heparinized blood sample
by Ficoll/Hypaque density gradient centrifugation. In each case, an aliquot of 1  106 to 2  106 PBMCs
was frozen for later DNA extraction to determine the HLA genotype and EBV genome loads, while the
remaining PBMCs were cryopreserved as duplicate ampoules in RPMI 1640 with 20% fetal calf serum and
10% dimethyl sulfoxide. Plasma was frozen to identify EBV and CMV serostatus. These samples were
studied in parallel with cryopreserved PBMC and frozen plasma samples collected prospectively from IM
patients during the acute phase and at later times after the resolution of symptoms (16, 61). Full blood
counts to determine lymphocyte numbers were performed at the Hematology Laboratory, Queen
Elizabeth Hospital, Birmingham, United Kingdom.
Determining EBV and CMV serostatus. Serial dilutions of plasma were assayed for the presence of
IgM and IgG antibodies to EBV VCA by indirect immunoﬂuorescence as described previously (62); as
VCA-positive and -negative target cells, the Akata-BL and EBV-loss Akata-BL lines were used in the IgM
assay, and the P3HR1 and BJAB lines were used in the IgG assay. The titers of IgG antibodies to EBNA1
were determined using a commercially available diagnostic enzyme-linked immunosorbent assay ac-
cording to the manufacturer’s instructions (Diamedix, Miami, FL). CMV serostatus was determined as
described previously (63).
Determining EBV genome load in PBMCs. Genomic DNA was isolated from PBMC pellets using a
GenElute blood genomic DNA kit (Sigma-Aldrich) according to the manufacturer’s instructions. DNA was
eluted into 80 l buffer, quantiﬁed using a NanoDrop spectrophotometer, and stored at 20°C. A
multiplex quantitative PCR assay which simultaneously ampliﬁes EBV BALF5 (DNA polymerase) and
cellular beta-2-microglobulin sequences was used to determine the EBV genome load (64); four
replicate samples of 500 ng DNA (each equivalent to 1.5  105 cells) were assayed for each PBMC
Abbott et al. Journal of Virology
November 2017 Volume 91 Issue 21 e00382-17 jvi.asm.org 20
 o
n
 O
ctober 19, 2017 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
preparation. All standards and samples were tested in triplicate, and the data were analyzed using
SDS (v1.4) software.
Flow cytometric analysis of EBV-speciﬁc and total T cell populations. Tetramers were used to
identify and analyze the surface marker phenotype of EBV-speciﬁc CD8 T cells. In addition to CD3 and
CD8, cell surface CD45RA and CCR7 were used to identify the naive (CD45RA CCR7), central memory
(CD45RA CCR7), effector memory (CD45RA CCR7), and revertant memory (CD45RA CCR7) T cell
subsets. Staining for cell surface HLA-DR and CD38 and for intracellular Bcl2 was used to identify
activated (HLA DR CD38 Bcl2low) T cells. Tetramer staining identiﬁed CD8 T cells speciﬁc for the
following epitopes derived from individual EBV lytic or latent cycle proteins (see below): YVLDHLIVV (lytic,
BRLF1), GLCTLVAML (lytic, BMLF1), LLIEGIFFI (lytic, BaRF1), or CLGGLLTMV (latent, LMP2), which are
restricted through HLA-A*0201, or RPRATWIQEL (lytic, BaRF1), TPSVSSSISSL (lytic, BFRF3), or RPPIFIRRL
(latent, EBNA3A) (14), which are restricted through HLA-B*0702. Epitopes are designated by their initial
three residues (underlined).
Tetramer and antibody staining of cryopreserved PBMCs was performed as follows. Cells were
thawed and stained with LIVE/DEAD ﬁxable Aqua Dead cell stain (Molecular Probes, Thermo Fisher
Scientiﬁc) for 15 min at room temperature, washed, and stained with tetramer-phycoerythrin (PE) for 15
min at 37°C. Following two further washes, surface staining with the following was performed in Brilliant
stain buffer (BD Biosciences) for 30 min at 4°C: anti-CD14-Paciﬁc Green (clone SJ25-C1) and anti-CD19-
Paciﬁc Green (clone TüK4) (both from Molecular Probes, Thermo Fisher Scientiﬁc); anti-CD3-BV786 (clone
SK7), anti-CD8-allophycocyanin (APC)-H7 (clone SK1), anti-CD45RA-BV605 (clone HI100), and anti-
CD45RO-BV711 (clone UCHL1) (all from BD Biosciences); anti-CD38-peridinin chlorophyll protein (PerCP)-
Cy5.5 (clone HIT2) and anti-HLA-DR-APC (clone L243) (both from BioLegend); and anti-CCR7-ﬂuorescein
isothiocyanate (clone 150503; R&D Systems). Following ﬁxation and permeabilization using a Cytoﬁx/
Cytoperm kit (BD Biosciences), intracellular staining with anti-Ki67-BV421 (clone B56) and anti-Bcl-2-PE-
CF594 (clone 563601) (both from BD Biosciences) was performed in Brilliant stain and Perm/Wash buffer
(both from BD Biosciences) for 30 min at 4°C.
Flow cytometry data were acquired with an LSR Fortessa X20 analyzer (BD Biosciences) with standard
ﬁlter sets. Data were analyzed using Kaluza (v1.3) software (Beckman Coulter), and ﬁgures were created
using FlowJo software (TreeStar). CD3 T cells were gated on within the single, viable, CD14 CD19
lymphocyte population, before CD8 T cells and CD8 tetramer-positive cells were selected for further
analysis of surface and/or intracellular marker expression.
Flow cytometry-based analysis of NK cells and DCs. PBMCs were thawed and washed twice in R10
medium (RPMI 1640 [Sigma-Aldrich] containing 10% fetal bovine serum, 50 IU/ml penicillin, and 50
g/ml streptomycin). Cells were counted and resuspended in R10 medium at a concentration of 2  106
cells/ml. NK cells were identiﬁed by staining 2  105 PBMCs with LIVE/DEAD violet amine dye (Life
Technologies), anti-CD19-Paciﬁc Blue (PB) (clone LT19; AbD Serotec), and anti-CD3-PB (clone SP34-2),
anti-CD14-PB (clone M5E2), and anti-CD56-PE-Cy7 (clone B159) (all from BD Bioscience) and gating on
live, lineage-negative lymphocytes expressing CD56 (Fig. 6A). Receptor expression on CD56 NK cells
and subsets thereof was evaluated using the following antibodies: anti-CD158a/h-biotin (KIR2DL1/S1
clone 11PB6; Miltenyi), anti-CD158b (KIR2DL2/L3/S2 clone CH-L; BD Bioscience), anti-CD158e1/e2
(KIR3DL1/S1 clone Z27) and anti-NKG2A-PE (clone Z199) (both from Beckman Coulter), and anti-
HLA-DR-APC (clone L243) (BioLegend). Streptavidin-Paciﬁc Orange (Life Technologies) was used to
detect anti-CD158a/h-biotin. Intracellular expression of Ki67 and Bcl2 was assayed as described
above for T cells.
DC subsets were identiﬁed by staining 5  105 PBMCs with LIVE/DEAD violet amine dye (Life Technol-
ogies); anti-HLA-DR-PerCP (clone L243; BD Bioscience); anti-CD123-PE-Cy7 (clone 7G3; eBioscience); anti-
CD11c-APC-H7 (custom conjugate; ReaMetrix); anti-CD3 (clone SP34-2), anti-CD14 PB (clone M5E2), and
anti-CD16 PB (clone 3G8) (all from BD Bioscience); anti-CD19-PB (clone LT19) and anti-CD20 (clone 2H7)
(both from AbD Serotec); and anti-CD56-PB (custom conjugate; ReaMetrix); gating on live, lineage-
negative mononuclear cells expressing HLA-DR cells; and then identifying pDC and mDC subsets within
this population on the basis of the differential expression of CD123 and CD11c (Fig. 7A).
Flow cytometry data were acquired with a Cyan ADP analyzer (Beckman Coulter) with standard ﬁlter
sets. Data were analyzed using FlowJo software (v8.8.6; TreeStar).
Plasma cytokine assays. Plasma levels of IFN-, IFN-, IL-1, IL-6, IL-10, IL-12, IL-18, TNF-, MIG/
CXCL9, and IP-10/CXCL10 were determined by a Luminex assay as described previously (65).
Statistical tests. All graphical data and statistical analyses were generated using Prism software (v5;
GraphPad Software Inc., San Diego, CA). The statistical signiﬁcance of differences between values
measured at the ﬁrst viremic time point and time points after 6 months in each group of subjects was
determined using a Mann-Whitney nonparametric test; P values of 0.05 were considered signiﬁcant.
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